Pharmacotherapy and pharmacogenetics of nicotine dependence.
about
Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 centuryPsychostimulant treatment of cocaine dependenceConstitutional mechanisms of vulnerability and resilience to nicotine dependenceIntegrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence.INTEGRATIVE BAYESIAN ANALYSIS OF NEUROIMAGING-GENETIC DATA THROUGH HIERARCHICAL DIMENSION REDUCTION.Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials.Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch.A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions.Genetic basis of delay discounting in frequent gamblers: examination of a priori candidates and exploration of a panel of dopamine-related lociThe self-medication hypothesis and psychostimulant treatment of cocaine dependence: an updateFactors associated with smoking cessationGender-stratified gene and gene-treatment interactions in smoking cessationClinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis.Public health in the genomic era: will Public Health Genomics contribute to major changes in the prevention of common diseases?The natural course of nicotine dependence symptoms among adolescent smokers.Genetics of nicotine dependence and pharmacotherapy.Smoking cessation and lung cancer: oncology nurses can make a difference.The influence of genetics on nicotine dependence and the role of pharmacogenetics in treating the smoking habit.Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.Mu opioids and their receptors: evolution of a concept.Substance use disorder genetic research: investigators and participants grapple with the ethical issues.Smoking cessation intervention: an evidence-based approach.A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation.Effect of single-nucleotide polymorphisms in ADH1B, ADH4, ADH1C, OPRM1, DRD2, BDNF, and ALDH2 genes on alcohol dependence in a Caucasian population.Defining the Scope of Public Engagement: Examining the "Right Not to Know" in Public Health Genomics.Brain imaging in substance abusers.Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy.
P2860
Q22305613-3AF4A120-A14C-4409-8697-42D4BAD488D0Q28267550-E1E58279-2E86-4B79-A43A-A6F97CAB66FDQ30365559-ADF1BB35-05F3-4F1E-9AB3-E4B44EE5488BQ31008696-9A7B4326-E3B2-49A7-AB37-72CAD9C62D71Q31146843-CF5077C5-C966-48A3-A856-D2CD35A5DBFCQ33351611-43C5B774-613F-4C57-83A5-EE7956E96B7DQ33609822-776D2EB5-550B-4C24-A179-612BCB674B90Q34037595-3A4A1313-B694-4B61-8D09-C81F5DC4B361Q34416823-0C239FF4-2B4F-4376-85D4-C31850315C21Q34487773-CD8EA22D-C74E-4EEB-8488-DA9DA7117ECEQ35281612-85BD7AB8-3EA5-4DB1-A82D-E8AAC32175FAQ35523896-B21B6C83-4CCE-483B-BA02-C86B1DAD6696Q35766564-3E175FA0-E113-4213-AB50-EF8808609988Q36050631-0D1B0BD4-9CD3-4B58-8CA2-5A1462DE08A6Q36217664-8A81BC59-32C1-429B-8F35-6183AF89FB5FQ36430709-6AF9F488-7C38-4657-B7C8-3B6F5446F2ACQ36453486-F9725923-2690-4100-9AFC-5D6AFE3DF82AQ36473699-F9B3F5E6-18D0-4BF7-9B8C-E878EEF8974EQ36792570-4FE66B4F-E95D-4FDE-B0DF-8FA1BE8195B7Q36829186-3AA53BED-80C7-4D22-8758-D51994B1172DQ36982933-A6D844C4-F566-4F7D-BBEC-567A9B6D5F97Q37079797-2621CBE7-A19D-4A6C-8D7A-F502DA729497Q37236111-DD90246C-E230-4629-A1C5-DEDA2110EED0Q37486121-DBBF358B-801E-4637-8234-F199E0BBF78AQ37702733-AA985DFB-90E7-45C5-839B-A2DD4CEC7C5DQ38016946-96BAF69E-67D8-45DE-9672-BD8394122CFFQ44631861-565766D1-6BF9-41F3-BC2C-3075BB61DBDCQ48084792-C81BCD07-4127-4447-B67A-68B09D91CA4BQ48709050-44E358D1-FB30-46B7-8906-16EF91C00EC1Q50767829-2867E4F7-5E45-4191-AB4D-FFFD888E6157Q54305284-34D92FCB-829A-4C3C-9E46-9EBE2FD3399F
P2860
Pharmacotherapy and pharmacogenetics of nicotine dependence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@ast
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@en
type
label
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@ast
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@en
prefLabel
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@ast
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@en
P1476
Pharmacotherapy and pharmacogenetics of nicotine dependence.
@en
P2093
Caryn E Lerman
Wade H Berrettini
P304
P356
10.1176/APPI.AJP.162.8.1441
P407
P577
2005-08-01T00:00:00Z